Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

Gene Therapy

Volumn 5, Issue 12, 1998, Pages 1593-1603

  Krisky, D M ^b   Wolfe, D ^b   Coins, W F ^b   Marconi, P C ^b   Ramakrishnan, R ^b   Mata, M ^b   Rouse, Rjd ^b   Fink, D J ^b   Glorioso, J C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Gene transfer; Herpes simplex virus; Primary neurons

Indexed keywords

TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; BRAIN CELL; CANCER CELL CULTURE; CELL CULTURE; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DORSAL ROOT; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GLIOSARCOMA; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; IMMEDIATE EARLY GENE; KIDNEY CELL; MONKEY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE; VERO CELL; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0032427040     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300766     Document Type: Article

References (14)

1. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
2. Johnson PA et al. Cytotoxicity of a replication-defective mutant herpes simplex virus type 1. J Virol 1992; 66: 2952-2965.
3. Wymer JP et al. Identification of immediate-early type cis-responsive elements in the promoter for the ribonucleotide reductase large subunit of herpes simplex virus type 2. J Virol 1989; 63: 2773-2784.
4. Yeh L, Schaffer PA. A novel class of transcripts expressed with late kinetics in the absence of ICP4 spans the junction between the long and short segments of the herpes simplex virus type 1 genome. J Virol 1993; 67: 7373-7382.
5. Johnson P, Wang M, Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the viron host shut-off function. J Virol 1994; 68: 6347-6362.
6. Wu N et al. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate - early genes encoding ICP4, ICP27 and ICP22. J Virol 1996; 70: 6358-6368.
7. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
8. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
9. Page B, Page M, Noel C. A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol 1993; 3: 473-476.
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
11. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Ann Rev Micro 1995; 49: 675-710.
12. Kramm CM et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
13. Kucharczuk JC et al. Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57: 466-471.
14. Fink DJ et al. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther 1992; 3: 11-19.